Amivantamab Shows Long-term Efficacy/Safety in Post-Platinum EGFR Exon 20 Insertion+ NSCLC
April 2nd 2023Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.
Cabozantinib Therapy Shows Early Efficacy in Advanced RCC After Checkpoint Inhibitor Combonation
February 18th 2023Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.
Acceptable Safety Seen With Orca-Q in the Haplo SCT Setting for High-risk Hematologic Malignancies
February 17th 2023At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.
No Survival Advantage When Chemotherapy Is Given Prior to Transplant in R/R AML
February 14th 2023In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall survival rates vs those given intense salvage chemotherapy first.
Yu Highlights Possible Sequencing Strategies in mCRPC
January 22nd 2023In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.
Percentage of Actionable Mutations in Prostate Cancer Underscores Importance of Testing
November 12th 2022During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.
Regorafenib Then Nivolumab Sequence Is Tolerable After First-Line HCC Treatment
October 14th 2022Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.
Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid Carcinoma
September 13th 2022Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.
First-line Olaparib Triplet Improves Outcomes in mCRPC
September 11th 2022Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.
Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28th 2022The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
Carfilzomib Plus Lenalidomide/Dexamethasone After Transplant Extends PFS Over Lenalidomide in MM
August 26th 2022Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.
Ibrutinib/Venetoclax Combination Improves MRD Negativity in Blood, Marrow in CLL
August 25th 2022Data from the planned interim analysis of the FLAIR trial show that venetoclax plus ibrutinib can achieved minimal residual disease negativity in patient with treatment-naïve chronic lymphocytic leukemia.